Predictive. Prognostic. Personalized.

Vesta is Valar Labs' genitourinary-focused portfolio of AI-powered pathology tests, designed to help physicians and patients make personalized, evidence-based decisions about cancer treatments.

Explore Tests
Order Vesta

The future of GU oncology is precision treatment. Lead the way with confidence.

Vesta Technology

Novel Biomarkers

Valar Labs' research team has developed and validated multiple unique Vesta biomarker models in over 1,000 patients with Non-Muscle Invasive Bladder Cancer (NMIBC) using histology features.

Expertly Trained AI

Valar Labs' board-certified pathologists created 500,000+ annotations of tumors and their microenvironment to train our Computational Histology Artificial Intelligence (CHAI) platform, grounding the technology in biology.

Fast, H&E-Based Testing

Leveraging existing tumor specimens, first-of-its-kind AI analyzes pathology slides and returns actionable results in days for timely treatment decisions.

Predict patients’ response to key anti-cancer treatments.

By unlocking key features of the tumor and its microenvironment, BCGPredict identifies patients at a higher risk of not responding to BCG.1,2

​Understand what’s best for each individual by adding personalized data to your clinical management strategy.3

2X

Biomarker-present patients have a 2x elevated risk of non-response to BCG compared to biomarker-absent patients.

​Patients who test biomarker-present demonstrated a higher likelihood of success with an alternative therapy.

Personalized risk of recurrence and progression.

Whatever your clinical care strategy, deeper insights based on tumor biology enable a more personalized plan.

​

Prognostic models stratify risks of high-grade recurrence and muscle-invasive progression better than existing guideline frameworks.1,4

​

Individual patient risk scores and projected actual risks over time can aid in patient counseling for surveillance, monitoring, and surgical management decisions.

2X

Patients with high recurrence scores have a 2x elevated risk of high-grade recurrence over up to 24 months.

4X

Patients with a high progression score have an almost 4x elevated risk of disease progression within 3 years.

If we had waited the time to do standard re-resection, BCG, and imaging, 18 weeks would have passed, and he likely would have progressed to metastatic incurable disease. The Valar test saved his life.

Gautum Agarwal, MD

Urologic Oncologist. Director, Precision Medicine, Mercy Clinic

The introduction of Vesta is a paradigm shift for how we can best serve our bladder cancer patients. Its ability to predict response to BCG treatment is invaluable, particularly amidst the current nationwide BCG shortage. This breakthrough allows us to judiciously allocate our limited BCG therapy and responsibly pursue the best option for each patient. This ensures each patient receives personalized and highly effective treatment.

Jay Shah

Urologist, Stanford Health Care

The introduction of Vesta has been transformative to my practice. The ability to predict which of my patients won’t respond to BCG and route them to an alternative is a paradigm shift in bladder cancer treatment. Its seamless integration into our existing workflows has also been invaluable.

Stephen Williams

Urologist, UTMB

Are you a:

Patient
Patient

Check out this informational brochure to better understand how Vesta can give you and your doctor a more personalized view of your cancer.

Learn more
Healthcare Professional
Healthcare Professional

Download our one pager here.
Ready to incorporate Vesta into your practice?

Get in touch
Learn More
Industry Partner
Industry Partner

Partner with us to run validation studies for novel cancer therapies.

Work with us

Frequently asked questions about Vesta

What is Vesta?

Vesta is Valar Labs’ GU-focused portfolio of AI-powered diagnostic tests, providing deep insights into each patient’s unique disease using routine histology. Vesta tests are currently available in bladder cancer, with other indications in development.

Who is Vesta intended for?

Vesta Bladder tests are intended for patients with non-muscle invasive bladder cancer. Vesta Bladder Risk Stratify provides individualized risks of disease recurrence and progression, and Vesta Bladder BCGPredict is the only bladder cancer diagnostic that predicts treatment response to BCG, through histology alone.

How much does Vesta testing cost?

Valar Labs is committed to providing patient access regardless of finances. Our Financial Access Program supports patients with financial needs.

What is the turnaround time for the test?

You can expect Vesta Bladder test results back within approximately 3 days after the sample has arrived at our laboratory.

How can I order Vesta testing?

Vesta Bladder testing is offered through licensed physicians who treat patients with bladder cancer. Vesta tests are performed in Valar Labs’ CLIA-certified laboratory.

Do I need an additional sample to run Vesta?

No, Vesta Bladder testing uses an existing sample from routine procedures already performed to diagnose bladder cancer. No additional procedure or sample collection is needed.

When is Vesta ordered in my diagnostic process?

Vesta Bladder testing can be ordered after a bladder cancer diagnosis is made to help clinical management planning.

News & Resources

Latest News

Development and Validation of a Computational Histology Artificial Intelligence–Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer

Journal of Clinical Oncology

February 11, 2026

Valar Labs Publishes Pivotal Study in Journal of Clinical Oncology Validating AI to Predict Chemotherapy Response for Pancreatic Cancer Patients

Businesswire

February 11, 2026

Artificial Intelligence Biomarkers Predict Poor Efficacy of Bacillus Calmette-Guérin Rechallenge in Previously Bacillus Calmette-Guérin–Treated Nonmuscle-Invasive Bladder Cancer

Journal of Urology

July 1, 2025

Ready for Vesta?

Get in touch

1. Lotan Y, Krishna V, Abuzeid WM, et al. Predicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence–Powered Pathology Assay: Development and Validation in an International 12-Center Cohort. J Urol. 2025;213(2):192-204. 2. Lotan Y, Li R, Chang SS. AI Biomarkers Predict Poor Efficacy of BCG Rechallenge in Previously BCG-Treated Non-muscle Invasive Bladder Cancer. J Urol. Published online April 16, 2025. doi:10.1097/JU.0000000000004541 3. Packiam VT, McElree IM, Ghodoussipour S, et al. Presence of an Artificial Intelligence-powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. Published online April 25, 2025. doi:10.1016/j.euo.2025.04.006 4. Chang SS, Launer B, Narayan V, et al. Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current European Association of Urology and American Urological Association Stratification Schemes. Eur Urol. Published online June 12, 2025. doi:10.1016/j.eururo.2025.05.035